1136869--3/2/2006--ZIMMER_HOLDINGS_INC

related topics
{regulation, government, change}
{operation, international, foreign}
{customer, product, revenue}
{property, intellectual, protect}
{product, market, service}
{acquisition, growth, future}
{financial, litigation, operation}
{loss, insurance, financial}
{regulation, change, law}
We are subject to cost-containment efforts of healthcare purchasing organizations, which may have a material adverse effect on our financial condition and results of operations. We are involved in an ongoing investigation by the United States Department of Justice of companies in the orthopaedics industry, the results of which may have a material adverse effect on our sales, financial condition and results of operations. We and our customers are subject to various governmental regulations and we may incur significant expenses to comply with these regulations and develop products compatible with these regulations. We are subject to health care fraud and abuse regulations that could require us to change our business practices and restrict our operations in the future. We may incur product liability losses, and insurance coverage may be inadequate or unavailable to cover these losses. RISKS RELATED TO OUR BUSINESS If we fail to effectively utilize the skills and knowledge of orthopaedic surgeons, customers may not buy our products and our revenue and profitability may decline. If we fail to retain the independent agents and distributors upon whom we rely heavily to market our products, customers may not buy our products and our revenue and profitability may decline. If we do not introduce new products in a timely manner, our products may become obsolete over time, customers may not buy our products and our revenue and profitability may decline. We conduct a significant amount of our sales activity outside of the United States, which subjects us to additional business risks and may cause our profitability to decline due to increased costs. We are subject to risks arising from currency exchange rate fluctuations, which can increase our costs and may cause our profitability to decline. We may fail to adequately protect our proprietary technology and other intellectual property, which would allow competitors or others to take advantage of our research and development efforts. We may be subject to intellectual property litigation and infringement claims, which could cause us to incur significant expenses or prevent us from selling our products. We may complete additional acquisitions, which could increase our costs or liabilities or be disruptive. If we are unable to form strategic alliances, or if our strategic alliances fail to achieve their objectives, our operating results will be negatively impacted. We depend on a limited number of suppliers for some key raw materials and outsourced activities.

Full 10-K form ▸

related documents
1136869--2/28/2007--ZIMMER_HOLDINGS_INC
876167--2/13/2007--PROGRESS_SOFTWARE_CORP_/MA
33113--5/12/2009--ENVIRONMENTAL_TECTONICS_CORP
1125011--3/16/2006--KANBAY_INTERNATIONAL_INC
856982--3/10/2010--MERIT_MEDICAL_SYSTEMS_INC
33113--5/29/2008--ENVIRONMENTAL_TECTONICS_CORP
876167--1/29/2008--PROGRESS_SOFTWARE_CORP_/MA
900017--4/6/2007--THOMAS_GROUP_INC
33113--5/24/2007--ENVIRONMENTAL_TECTONICS_CORP
920527--5/26/2010--PSS_WORLD_MEDICAL_INC
33113--5/27/2010--ENVIRONMENTAL_TECTONICS_CORP
1047122--2/27/2008--RAYTHEON_CO/
40533--2/22/2008--GENERAL_DYNAMICS_CORP
883980--2/23/2007--FIRST_DATA_CORP
820736--2/22/2008--ORBITAL_SCIENCES_CORP_/DE/
799729--9/8/2006--PAREXEL_INTERNATIONAL_CORP
739708--3/1/2007--CLEAR_CHANNEL_COMMUNICATIONS_INC
913165--3/16/2007--EXACTECH_INC
1026650--3/3/2010--ERESEARCHTECHNOLOGY_INC_/DE/
352079--3/14/2006--TVI_CORP
910329--3/17/2008--MEDIFAST_INC
876167--1/29/2009--PROGRESS_SOFTWARE_CORP_/MA
1000228--2/24/2009--HENRY_SCHEIN_INC
932696--5/12/2009--INSIGHT_ENTERPRISES_INC
1099800--2/26/2010--Edwards_Lifesciences_Corp
812191--3/14/2007--REHABCARE_GROUP_INC
894253--2/25/2009--PEROT_SYSTEMS_CORP
856982--3/4/2009--MERIT_MEDICAL_SYSTEMS_INC
320121--4/23/2007--TELOS_CORP
320121--3/31/2010--TELOS_CORP